S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   400.08 (+2.27%)
AAPL   160.47 (+2.33%)
MSFT   337.20 (+2.28%)
FB   336.69 (+1.07%)
GOOGL   2,916.90 (+2.58%)
AMZN   3,561.01 (+1.61%)
TSLA   1,139.61 (+5.33%)
NVDA   334.68 (+6.24%)
BABA   131.68 (-1.25%)
NIO   40.42 (+1.08%)
CGC   11.07 (-5.30%)
AMD   162.23 (+4.79%)
GE   98.33 (+0.50%)
MU   86.13 (+3.25%)
T   23.90 (-1.32%)
F   19.67 (-0.41%)
DIS   147.85 (-0.18%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   52.35 (-3.06%)
BA   198.10 (-0.56%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   400.08 (+2.27%)
AAPL   160.47 (+2.33%)
MSFT   337.20 (+2.28%)
FB   336.69 (+1.07%)
GOOGL   2,916.90 (+2.58%)
AMZN   3,561.01 (+1.61%)
TSLA   1,139.61 (+5.33%)
NVDA   334.68 (+6.24%)
BABA   131.68 (-1.25%)
NIO   40.42 (+1.08%)
CGC   11.07 (-5.30%)
AMD   162.23 (+4.79%)
GE   98.33 (+0.50%)
MU   86.13 (+3.25%)
T   23.90 (-1.32%)
F   19.67 (-0.41%)
DIS   147.85 (-0.18%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   52.35 (-3.06%)
BA   198.10 (-0.56%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   400.08 (+2.27%)
AAPL   160.47 (+2.33%)
MSFT   337.20 (+2.28%)
FB   336.69 (+1.07%)
GOOGL   2,916.90 (+2.58%)
AMZN   3,561.01 (+1.61%)
TSLA   1,139.61 (+5.33%)
NVDA   334.68 (+6.24%)
BABA   131.68 (-1.25%)
NIO   40.42 (+1.08%)
CGC   11.07 (-5.30%)
AMD   162.23 (+4.79%)
GE   98.33 (+0.50%)
MU   86.13 (+3.25%)
T   23.90 (-1.32%)
F   19.67 (-0.41%)
DIS   147.85 (-0.18%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   52.35 (-3.06%)
BA   198.10 (-0.56%)
S&P 500   4,655.27 (+1.32%)
DOW   35,135.94 (+0.68%)
QQQ   400.08 (+2.27%)
AAPL   160.47 (+2.33%)
MSFT   337.20 (+2.28%)
FB   336.69 (+1.07%)
GOOGL   2,916.90 (+2.58%)
AMZN   3,561.01 (+1.61%)
TSLA   1,139.61 (+5.33%)
NVDA   334.68 (+6.24%)
BABA   131.68 (-1.25%)
NIO   40.42 (+1.08%)
CGC   11.07 (-5.30%)
AMD   162.23 (+4.79%)
GE   98.33 (+0.50%)
MU   86.13 (+3.25%)
T   23.90 (-1.32%)
F   19.67 (-0.41%)
DIS   147.85 (-0.18%)
ACB   6.45 (-5.01%)
AMC   36.85 (-2.07%)
PFE   52.35 (-3.06%)
BA   198.10 (-0.56%)
NASDAQ:SRRA

Sierra Oncology Stock Forecast, Price & News

$23.15
+0.42 (+1.85%)
(As of 11/29/2021 03:59 PM ET)
Add
Compare
Today's Range
$22.76
$23.62
50-Day Range
$19.19
$23.20
52-Week Range
$13.32
$23.94
Volume
3,161 shs
Average Volume
36,986 shs
Market Capitalization
$348.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.84
30 days | 90 days | 365 days | Advanced Chart
Receive SRRA News and Ratings via Email

Sign-up to receive the latest news and ratings for Sierra Oncology and its competitors with MarketBeat's FREE daily newsletter.


Sierra Oncology logo

About Sierra Oncology

Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focuses on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SRRA
Previous Symbol
NASDAQ:DNAI
Fax
N/A
Employees
69
Year Founded
N/A

Sales & Book Value

Annual Sales
$300 thousand
Book Value
$6.31 per share

Profitability

Net Income
$-80.90 million
Pretax Margin
-43,527.50%

Debt

Price-To-Earnings

Miscellaneous

Free Float
4,866,000
Market Cap
$348.52 million
Optionable
Optionable

Company Calendar

Last Earnings
11/05/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/10/2022

MarketRank

Overall MarketRank

2.73 out of 5 stars

Medical Sector

48th out of 1,392 stocks

Pharmaceutical Preparations Industry

13th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 5.0Valuation: 0.6 5 -4 -3 -2 -1 -












Sierra Oncology (NASDAQ:SRRA) Frequently Asked Questions

Is Sierra Oncology a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sierra Oncology in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sierra Oncology stock.
View analyst ratings for Sierra Oncology
or view top-rated stocks.

How has Sierra Oncology's stock been impacted by Coronavirus (COVID-19)?

Sierra Oncology's stock was trading at $11.60 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SRRA shares have increased by 99.6% and is now trading at $23.15.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Sierra Oncology?

Sierra Oncology saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 46,800 shares, a drop of 27.2% from the October 31st total of 64,300 shares. Based on an average daily volume of 42,200 shares, the days-to-cover ratio is presently 1.1 days. Currently, 1.1% of the company's shares are sold short.
View Sierra Oncology's Short Interest
.

When is Sierra Oncology's next earnings date?

Sierra Oncology is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Sierra Oncology
.

How were Sierra Oncology's earnings last quarter?

Sierra Oncology, Inc. (NASDAQ:SRRA) issued its quarterly earnings results on Friday, November, 5th. The biotechnology company reported ($2.10) EPS for the quarter, missing analysts' consensus estimates of ($1.78) by $0.32.
View Sierra Oncology's earnings history
.

What price target have analysts set for SRRA?

2 analysts have issued 1-year target prices for Sierra Oncology's stock. Their forecasts range from $33.00 to $35.00. On average, they expect Sierra Oncology's stock price to reach $34.00 in the next twelve months. This suggests a possible upside of 46.9% from the stock's current price.
View analysts' price targets for Sierra Oncology
or view top-rated stocks among Wall Street analysts.

Who are Sierra Oncology's key executives?

Sierra Oncology's management team includes the following people:
  • Stephen George Dilly, President, Chief Executive Officer & Director (LinkedIn Profile)
  • Emma McCann, SVP-Operations & Program Management
  • Sukhi Jagpal, Chief Financial Officer
  • Mark M. Kowalski, Chief Medical Officer
  • Diane Gardiner, Senior VP-Human Resources & Administration

What other stocks do shareholders of Sierra Oncology own?

What is Sierra Oncology's stock symbol?

Sierra Oncology trades on the NASDAQ under the ticker symbol "SRRA."

Who are Sierra Oncology's major shareholders?

Sierra Oncology's stock is owned by many different institutional and retail investors. Top institutional investors include Rock Springs Capital Management LP (8.73%), Caxton Corp (2.94%), New Leaf Venture Partners L.L.C. (2.72%), Renaissance Technologies LLC (0.70%), Millennium Management LLC (0.65%) and Pura Vida Investments LLC (0.49%). Company insiders that own Sierra Oncology stock include Barbara Klencke, Craig A Collard and Stephen George Dilly.
View institutional ownership trends for Sierra Oncology
.

Which major investors are selling Sierra Oncology stock?

SRRA stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Pura Vida Investments LLC, Caxton Corp, BlackRock Inc., and Renaissance Technologies LLC.
View insider buying and selling activity for Sierra Oncology
or view top insider-selling stocks.

Which major investors are buying Sierra Oncology stock?

SRRA stock was purchased by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Rock Springs Capital Management LP, Two Sigma Advisers LP, Two Sigma Investments LP, Geode Capital Management LLC, Jackson Square Capital LLC, and Dimensional Fund Advisors LP. Company insiders that have bought Sierra Oncology stock in the last two years include Barbara Klencke, Craig A Collard, and Stephen George Dilly.
View insider buying and selling activity for Sierra Oncology
or or view top insider-buying stocks.

How do I buy shares of Sierra Oncology?

Shares of SRRA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sierra Oncology's stock price today?

One share of SRRA stock can currently be purchased for approximately $23.15.

How much money does Sierra Oncology make?

Sierra Oncology has a market capitalization of $348.52 million and generates $300 thousand in revenue each year. The biotechnology company earns $-80.90 million in net income (profit) each year or ($7.11) on an earnings per share basis.

How many employees does Sierra Oncology have?

Sierra Oncology employs 69 workers across the globe.

What is Sierra Oncology's official website?

The official website for Sierra Oncology is www.sierraoncology.com.

Where are Sierra Oncology's headquarters?

Sierra Oncology is headquartered at 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8.

How can I contact Sierra Oncology?

Sierra Oncology's mailing address is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company can be reached via phone at (604) 558-6536 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.